Indication
Anemia due to myelodysplastic syndrome
Anemia due to myelodysplastic syndrome is a hematologic complication characterized by a clinically significant deficiency of mature red blood cells and hemoglobin resulting from an underlying clonal hematopoietic stem cell disorder. Read more about Anemia due to myelodysplastic syndrome
3 drugs 3 manufacturers
Drugs that treat it
Common Anemia due to myelodysplastic syndrome therapies.
REBLOZYL (luspatercept-aamt)
RYTELO (imetelstat sodium)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAnemia due to myelodysplastic syndrome is a hematologic complication characterized by a clinically significant deficiency of mature red blood cells and hemoglobin resulting from an underlying clonal hematopoietic stem cell disorder.
Predominantly affecting older adults, it arises within the bone marrow due to ineffective erythropoiesis accompanied by cellular dysplasia and premature apoptotic death of erythroid precursors.
Patients typically present with symptoms of reduced oxygen delivery, such as profound fatigue, weakness, and exertional dyspnea.
The condition frequently manifests as a macrocytic or normocytic anemia and, without disease-directed intervention, often leads to chronic transfusion dependence with an associated risk of secondary iron overload.
- nih.gov
Anemia due to myelodysplastic syndrome is a hematologic complication characterized by a clinically significant deficiency of mature red blood cells and hemoglobin resulting from an underlying clonal hematopoietic stem cell disorder
- nih.gov
Anemia due to myelodysplastic syndrome is a hematologic complication characterized by a clinically significant deficiency of mature red blood cells and hemoglobin resulting from an underlying clonal hematopoietic stem cell disorder
- nih.gov
Predominantly affecting older adults, it arises within the bone marrow due to ineffective erythropoiesis accompanied by cellular dysplasia and premature apoptotic death of erythroid precursors
- nih.gov
Predominantly affecting older adults, it arises within the bone marrow due to ineffective erythropoiesis accompanied by cellular dysplasia and premature apoptotic death of erythroid precursors Patients typically present with symptoms of reduced oxygen delivery, such as profound fatigue, weakness, and exertional dyspnea The condition frequently manifests as a macrocytic or normocytic anemia and, without disease-directed intervention, often leads to chronic transfusion dependence with an associate...
- merckmanuals.com
The condition frequently manifests as a macrocytic or normocytic anemia and, without disease-directed intervention, often leads to chronic transfusion dependence with an associated risk of secondary iron overload
- nih.gov
The condition frequently manifests as a macrocytic or normocytic anemia and, without disease-directed intervention, often leads to chronic transfusion dependence with an associated risk of secondary iron overload
Personalize your experience
Follow Anemia due to myelodysplastic syndrome and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.